A systematic review of the interobserver variability for histology in the differentiation between squamous and nonsquamous non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 1, 2011, Pages 55-63

  Paech, Daniel C ^a   Weston, Adèle R ^a   Pavlakis, Nick ^b   Gill, Anthony ^c   Rajan, Narayan ^d   Barraclough, Helen ^e   Fitzgerald, Bronwyn ^d   Van Kooten, Maximiliano ^f  

^a Health Technology Analysts Pty Ltd   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Health Outcomes Eli Lilly Australia   (Australia)

^e ICIS Oncology Eli Lilly Level 1   (Australia)

^f Eli Lilly Australia   (Australia)

Author keywords

Histology; Lung cancer; Non small cell; Systematic review

Indexed keywords

CANCER CLASSIFICATION; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TUMOR DIFFERENTIATION;

EID: 78651069318     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181fc0878     Document Type: Article

References (41)

1. Key TJ, Schatzkin A, Willett WC, et al. Diet, nutrition and the prevention of cancer. Public Health Nutr 2004;7:187-200.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Idowu MO, Fuller CE, Powers CN. Non-small cell lung carcinoma: a diagnosis beyond its prime. Pathol Case Rev 2009;14:199-205.
4. Hirsch FR, Spreafico A, Novello S, et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008;3:1468-1481.
5. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-263.
6. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-1057.
7. Maeda T, Ueoka H, Tabata M, et al. Prognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicate poor prognosis. Jpn J Clin Oncol 2000;30:534-541.
8. World Health Organization. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: International Agency for Research on Cancer, 2004.
9. The World Health Organization. Histological typing of lung tumours. Second edition. Am J Clin Pathol 1982;77:123-136.
10. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) [abstract]. J Thorac Oncol 2007;2:S851.
11. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
12. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
13. Ciuleanu TE, Brodowicz T, Belani CP, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study. J Clin Oncol 2008;26:426s.
14. Ho CM, Lam WK. Recent advances in the management of non-small cell lung cancer. Med Bull 2007;12:13-17.
15. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-1596.
16. Felip E, Pavlidis N, Stahel RA; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow- up of small-cell lung cancer (SCLC). Ann Oncol 2005;16:i30-i31.
17. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
18. Food and Drug Administration. FDA Briefing Document Oncology Drug Advisory Committee Meeting [Food and Drug Administration On-line]. Available at: http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009- 4427b1-01-FDA.pdf. Accessed October 21, 2009.
19. Colby TV, Tazelaar HD, Travis WD, et al. Pathologic review of the Mayo Lung Project cancers [corrected]. Is there a case for misdiagnosis or overdiagnosis of lung carcinoma in the screened group? Cancer 2002;95:2361-2365.
20. Feinstein AR, Gelfman NA, Yesner R. Observer variability in the histopathologic diagnosis of lung cancer. Am Rev Respir Dis 1970;101: 671-684.
21. Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst 2004;96:1105-1107.
22. Fontham ET, Correra P, WuWilliams A, et al. Lung cancer in nonsmoking women: a multicentre case-control study. Cancer Epidemiol Biomarkers Prev 1991;1:35-43.
23. Greenberg ER, Korson R, Baker J. Incidence of lung cancer by cell type: a population-based study in New Hampshire and Vermont. J Natl Cancer Inst 1984;72:599-603.
24. Hanai A, Whittaker JS, Tateishi R, et al. Concordance of histological classification of lung cancer with special reference to adenocarcinoma in Osaka, Japan, and the North-West Region of England. Int J Cancer 1987;39:6-9.
25. Lipford EH 3rd, Eggleston JC, Lillemoe KD, et al. Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung. Am J Surg Pathol 1984;8:357-365.
26. Stanley KE, Matthews MJ. Analysis of a pathology review of patients with lung tumors. J Natl Cancer Inst 1981;66:989-992.
27. Merlin T, Weston A, Tooher R. Extending an evidence hierarchy to include topics other than treatment: revising the Australian 'levels of evidence.' BMC Med Res Methodol 2009;9:34.
28. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
29. Burnett RA, Swanson Beck J, Howatson SR, et al. Observer variability in histopathological reporting of malignant bronchial biopsy specimens. J Clin Pathol 1994;47:711-713.
30. Burnett RA, Howatson SR, Lang S, et al. Observer variability in histopathological reporting of non-small cell lung carcinoma on bronchial biopsy specimens. J Clin Pathol 1996;49:130-133.
31. Kreuzer M, Müller KM, Brachner A, et al. Histopathologic findings of lung carcinoma in German uranium miners. Cancer 2000;89:2613-2621.
32. Yamamoto S, Sobue T, Yamaguchi N, et al. Reproducibility of diagnosis and its influence on the distribution of lung cancer by histologic type in Osaka, Japan. Jpn J Cancer Res 2000;91:1-8.
33. Stang A, Pohlabeln H, Müller KM, et al. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer 2006;52:29-36.
34. Brownson RC, Loy TS, Ingram E, et al. Lung cancer in nonsmoking women: histology and survival patterns. Cancer 1995;75:29-33.
35. Campobasso O, Andrion A, Ribotta M, et al. The value of the 1981 WHO histological classification in inter-observer reproducibility and changing pattern of lung cancer. Int J Cancer 1993;53:205-208.
36. World Health Organization. Histological typing of lung tumours. Tumori 1981;67:253-272.
37. Grilley-Olson JE, Hayes DN, Qaqish BF, et al. Diagnostic reproducibility of squamous cell carcinoma (SC) in the era of histology-directed non-small cell lung cancer (NSCLC) chemotherapy: a large prospective study [abstract]. J Clin Oncol 2009;27:409s (abstr 8008).
38. Olak J, Ng A. Diagnosis and treatment of early-stage non-small cell lung cancer. Oncologist 1996;1:201-209.
39. Sobin LH. New techniques and tumor nomenclature. APMIS Suppl 1991;23:9-12.
40. Loo PS, Thomas SC, Nicolson MC, et al. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010;5:442-447.
41. Travis WD, Colby TV, Corrin B, et al. In collaboration with Sobin LH and Pathologists from 14 Countries. World Health Organization International Histological Classification of Tumours. Histological Typing of Lung and Pleural Tumours. 3rd Ed. New York: Springer-Verlag, 1999.